Research programme: arthritis therapy - Galapagos/ZoBio/Pyxis Discovery/Leiden University

Drug Profile

Research programme: arthritis therapy - Galapagos/ZoBio/Pyxis Discovery/Leiden University

Alternative Names: Arthritis therapy research programme - Galapagos, ZoBio, Pyxis Discovery, Leiden University

Latest Information Update: 24 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV; Leiden University; Pyxis Discovery; ZoBio
  • Developer Galapagos NV; Pyxis Discovery; ZoBio
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 24 May 2010 Discontinued - Preclinical for Rheumatic disorders in Netherlands (unspecified route)
  • 12 Aug 2005 Preclinical trials in Rheumatic disorders in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top